万泰生物：拟变更72.997万股回购股份用途并注销

Core Viewpoint - The company plans to change the purpose of repurchased shares from employee stock ownership plans to cancellation and reduction of registered capital, which will slightly decrease the total share capital without significant financial impact [1] Summary by Relevant Sections - Shareholder Meeting: The company will hold its first extraordinary general meeting of 2025 on October 31, 2025, to discuss the proposal regarding the change in the use of repurchased shares [1] - Share Repurchase Details: The company intends to repurpose 729,970 shares that have been repurchased but not yet utilized, changing their use from "for employee stock ownership plans or equity incentives" to "for cancellation and reduction of registered capital" [1] - Impact on Total Share Capital: Following the cancellation, the total share capital will decrease from 1,265,122,774 shares to 1,264,392,804 shares, indicating a minor adjustment in the company's capital structure [1] - Financial Implications: The proposed changes are not expected to have a significant impact on the company's financials and do not harm shareholder interests [1]